The birthday of a new syndrome: IgG4-related diseases constitute a clinical entity

Cervicothoracic spinal cord compression caused by IgG4-related sclerosing pachymeningitis: a case report and literature review

“…Kamisawa [4] confirmed IgG4-positive plasma cells, CD4-positive and CD8-positive T cell infiltration in AIP patients' pancreas, biliary tract, portal area of liver, lymph nodes in 2003; he also pointed out that AIP is not simply pancreatitis but a systemic disease and named it as IgG4-related autoimmune disease or IgG4-related disease (IgG4-RD). In recent years, the concept of IgG4-RD has been widely recognized and was released in the journal of Autoimmun Rev in 2010 [5].…”

IgG4-Associated Tubulointerstitial Nephritis: Two Case Reports and a Literature Review

“…Therefore, a novel clinicopathological entity, IgG4-related sclerosing disease or IgG4-related systemic disease (IgG4-RSD), was proposed and AIP was determined to be a subset of IgG4-RSD that involved pancreatic lesions (5, 6). IgG4-RSD has been identified in nearly every organ system, including the liver, gallbladder and organs outside the gastrointestinal tract such as the salivary glands, lachrymal glands, breasts, lungs, adenohypophysis, retroperitoneum, lymph nodes and aorta (2,7,8). Although there are accumulating numbers of cases of IgG4-RSD, the number of patients with IgG4-related nephropathy is comparatively small.…”

Analysis of pancreatic endocrine function in patients with IgG4-related diseases, in whom autoimmune pancreatitis was ruled out by diagnostic imaging

“…Twenty-eight patients (15 males, mean age 62.1±9.9 years old) met the following inclusion criteria: (1) definite or probable IgG4RD using comprehensive diagnostic criteria for IgG4RD 2011 or diagnostic criteria for IgG4-related kidney disease [16,17]; (2) possible IgG4RD (if biopsy was not possible because of the difficulty of reaching the affected organ(s)) with typical clinical findings and images for IgG4RD [CT, gallium ( 67 Ga) scintigraphy, or FDG-PET] with successful corticosteroid therapy; (3) without malignant disease, vasculitis, tuberculosis, or Castleman's disease. We excluded (1) patients who were diagnosed with type 1 AIP by using 'Clinical Diagnostic Criteria of Autoimmune Pancreatitis 2006 in Japan' [18]; (2) patients who showed accumulation of fluorodeoxyglucose (FDG) in the pancreas with positron-emission tomography (PET), and also had inflammation in the pancreas; (3) patients with no clinical data about glucose tolerance, such as HbA1c, before glucocorticoid therapy (Fig. 1).…”